AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteCZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.
More Information Supplier PageCZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.
More Information Supplier PageCZC-54252 is a potent inhibitor of LRRK2 with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2 respectively.
More Information Supplier PageQuinic acid is an acid found in cinchona bark and is a versatile chiral starting material.
More Information Supplier PageD-(+)-Xylose is classified as a monosaccharide of the aldopentose type, which means that it contains five carbon atoms and includes a formyl functional group.
More Information Supplier PageD-106669 is a highly potent and selective PI3K inhibitor, (PI3Kα IC50 <10 nM, >3 log selectivity against tyrosine or serine/threonine kinases, except ERK1 and 2).
More Information Supplier PageD-106669 is a highly potent and selective PI3K inhibitor, (PI3Kα IC50 <10 nM, >3 log selectivity against tyrosine or serine/threonine kinases, except ERK1 and 2).
More Information Supplier PageD-106669 is a highly potent and selective PI3K inhibitor, (PI3Kα IC50 <10 nM, >3 log selectivity against tyrosine or serine/threonine kinases, except ERK1 and 2).
More Information Supplier PageD-106669 is a highly potent and selective PI3K inhibitor, (PI3Kα IC50 <10 nM, >3 log selectivity against tyrosine or serine/threonine kinases, except ERK1 and 2).
More Information Supplier PageD-64131 is a novel inhibitor of tubulin polymerization that inhibits tumor cell proliferation in vitro (IC50 = 74 nM).
More Information Supplier PageD-64131 is a novel inhibitor of tubulin polymerization that inhibits tumor cell proliferation in vitro (IC50 = 74 nM).
More Information Supplier PageD-64131 is a novel inhibitor of tubulin polymerization that inhibits tumor cell proliferation in vitro (IC50 = 74 nM).
More Information Supplier PageD-69491 (SU11464) is a small-molecule HER2 inhibitor, which was under development for the treatment of tumours with high expression of HER2, such as breast, ovarian, lung and pancreatic carcinomas.
More Information Supplier PageD-69491 (SU11464) is a small-molecule HER2 inhibitor, which was under development for the treatment of tumours with high expression of HER2, such as breast, ovarian, lung and pancreatic carcinomas.
More Information Supplier PageD-cycloserine is a partial agonist at the glycine receptor, and has been shown to have cognition-enhancing properties for models of Parkinsons disease in primates.
More Information Supplier PageD-cycloserine is a partial agonist at the glycine receptor, and has been shown to have cognition-enhancing properties for models of Parkinsons disease in primates.
More Information Supplier PageD-cycloserine is a partial agonist at the glycine receptor, and has been shown to have cognition-enhancing properties for models of Parkinsons disease in primates.
More Information Supplier PageD-glutamine is a D type stereoisomer of glutamine which is one of the 20 amino acids encoded by the standard genetic code.
More Information Supplier PageD-glutamine is a D type stereoisomer of glutamine which is one of the 20 amino acids encoded by the standard genetic code.
More Information Supplier PageD-glutamine is a D type stereoisomer of glutamine which is one of the 20 amino acids encoded by the standard genetic code.
More Information Supplier PageD-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
More Information Supplier PageD-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
More Information Supplier PageD-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
More Information Supplier PageD-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
More Information Supplier PageD-Mannitol is an osmotic diuretic agent and a weak renal vasodilator.
More Information Supplier PageD-Pinitol is a precursor for biologically active fluorinated isosteres of inositol.
More Information Supplier PageD-Pinitol is a precursor for biologically active fluorinated isosteres of inositol.
More Information Supplier PageD-Pinitol is a precursor for biologically active fluorinated isosteres of inositol.
More Information Supplier PageD2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.
More Information Supplier PageD2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.
More Information Supplier PageD2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.
More Information Supplier PageD2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.
More Information Supplier PageDabigatran etexilate mesylate is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
More Information Supplier PageDabigatran etexilate mesylate is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
More Information Supplier PageDabigatran etexilate mesylate is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.
More Information Supplier PageDabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
More Information Supplier PageDabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
More Information Supplier PageDabigatran ethyl ester, which is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
More Information Supplier PageDabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
More Information Supplier PageDabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
More Information Supplier PageDabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
More Information Supplier PageDabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
More Information Supplier PageDabrafenib is a potent and selective inhibitor of B-RAF protein kinase carrying V600E mutation, currently in clinical trial.
More Information Supplier PageDabrafenib Mesylate is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
More Information Supplier PageDabrafenib Mesylate is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
More Information Supplier PageDabrafenib Mesylate is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
More Information Supplier PageDacarbazine is an antineoplastic chemotherapy drug used in the treatment of various cancersDacarbazine is a member of the class of alkylating agents, which destroy cancer cells by adding an alkyl group (CnH2n+1) to its DNA.
More Information Supplier Page
